Despite our leeriness of it, Amiodorone is now working itself into first position as an antiarrhythmic for a variety of heart rhythm problems.
I ran across this in an article about treatments for ventricular tachycardia. It's practically a manifesto for its use.
In general on this site, it's been considered a dangerous drug with many side effects. It's been depicted as a convenience for doctors at the expense of the overall well-being of the patient ("my part of this person's problems is fixed"). It has been noted to take six months or more to leave a person's body after they stop taking it.
However, it has also been agreed that this can be a miracle-working drug when the chips are really down.
I guess we're going to find out over the next several years what the overall value and price of using amiodorone will be for a wide variety of patients. When it's gotten this far in recognition, it's very likely to become commonly prescribed for much more commonplace issues.
Best wishes,
I ran across this in an article about treatments for ventricular tachycardia. It's practically a manifesto for its use.
In general on this site, it's been considered a dangerous drug with many side effects. It's been depicted as a convenience for doctors at the expense of the overall well-being of the patient ("my part of this person's problems is fixed"). It has been noted to take six months or more to leave a person's body after they stop taking it.
However, it has also been agreed that this can be a miracle-working drug when the chips are really down.
I guess we're going to find out over the next several years what the overall value and price of using amiodorone will be for a wide variety of patients. When it's gotten this far in recognition, it's very likely to become commonly prescribed for much more commonplace issues.
emedicine.medscape.com said:Amiodarone (Cordarone)
Newest of the antiarrhythmics used in treating VT, generally is considered a class III antiarrhythmic, yet it has pharmacologic characteristics of all 4 classes.
Now is considered a class I intervention by the American College of Cardiology's practice guidelines for managing acute MI. DOC in treatment of refractory, hemodynamically unstable VT. Prehospital studies suggest amiodarone is safe for use in prehospital setting, and its adoption in the new ACLS guidelines will increasingly lead EMS authorities to adopt it as their first-line antiarrhythmic. This change already is well underway in Europe.
Interactions
Increases effect and blood levels of theophylline, quinidine, procainamide, phenytoin, methotrexate, flecainide, digoxin, cyclosporine, beta-blockers, and anticoagulants; ritonavir, sparfloxacin, and disopyramide increase cardiotoxicity; coadministration with calcium channel blockers may cause additive effects, further decreasing myocardial contractility; cimetidine may increase amiodarone levels
Best wishes,